Audentes Therapeutics, Inc. Financing Cash Flow
Audentes Therapeutics, Inc. reported Financing Cash Flow of $62.93 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2019-11-07
- Audentes Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2019-09-30 was $12.24M, a 876.62% increase year-over-year.
- Audentes Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2019-06-30 was $47.69M, a 202.94% increase year-over-year.
- Audentes Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2019-03-31 was $3.00M, a 98.62% decline year-over-year.
- Audentes Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2018-12-31 was $163.54M, a 5564.67% increase year-over-year.
- Audentes Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2018 was $398.46M, a 230.53% increase from fiscal 2017.
- Audentes Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2017 was $120.55M, a 59.96% increase from fiscal 2016.
- Audentes Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2016 was $75.36M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2019-09-30 | $12.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $59.92M derived: sum of 2 quarters · filed 2019-11-07 | $62.93M 10-Q · filed 2019-11-07 | $226.47M derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | $47.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $50.69M 10-Q · filed 2019-08-07 | $214.23M derived: sum of 3 quarters · filed 2019-08-07 | $215.48M derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-03-31 | $3.00M 10-Q · filed 2019-05-08 | $166.54M derived: sum of 2 quarters · filed 2019-05-08 | $167.80M derived: sum of 3 quarters · filed 2019-11-07 | $183.54M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-12-31 | $163.54M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $164.79M derived: sum of 2 quarters · filed 2019-11-07 | $180.53M derived: sum of 3 quarters · filed 2019-11-07 | $398.46M 10-K · filed 2019-03-01 |
| 2018-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $16.99M derived: sum of 2 quarters · filed 2019-11-07 | $234.92M 10-Q · filed 2019-11-07 | $237.81M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $15.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $233.67M 10-Q · filed 2019-08-07 | $236.56M derived: sum of 3 quarters · filed 2019-08-07 | $273.28M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $217.93M 10-Q · filed 2019-05-08 | $220.82M derived: sum of 2 quarters · filed 2019-05-08 | $257.54M derived: sum of 3 quarters · filed 2019-05-08 | |
| 2017-12-31 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $39.61M derived: sum of 2 quarters · filed 2019-03-01 | $120.55M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $36.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $117.67M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $80.94M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $75.36M 10-K · filed 2019-03-01 |